Primary open-angle glaucoma (POAG) or Ocular hypertension (OH)
Conditions
Interventions
0.03% SNJ-1656 instilled in both eyes, b.i.d. for 7 days.
0.05% SNJ-1656 instilled in both eyes, b.i.d. for 7 days.
0.1% SNJ-1656 instilled in both eyes, b.i.d. for 7 days.
Vehicle instilled in both
Sponsors
Senju Pharmaceutical co.,ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients had POAG or OH 2)Patents were likely to be controlled on glaucoma medication 3)IOP (hour 0) of >=22.0 mmHg and <=31.0 mmHg 4)Best corrected visual acuity of 0.5 or better
Exclusion criteria
Exclusion criteria: 1)Any active ocular disease other than glaucoma or OH 2)Active retinal disease 3)Ocular surgery within 3 months 4)History of keratorefractive surgery or filtering surgery 5)History of trabeculotomy in the study eye 6)Anticipated wearing of contact lenses 7)Uncontrolled systemic disease (eg, hepatic, renal, cardiovascular or endocrine system disease) 8)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy 9)Highly visual field loss (eg, the mean deviation <=15dB) 10)Corneal abnormalities that would preclude accurate readings with an applanation tonometer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean changes from baseline Intraocular pressure (IOP) at day 7 (Hour 0 and 2) | — |
Countries
Japan
Outcome results
None listed